Publication:
Drug Repositioning for Effective Prostate Cancer Treatment

Simple item page
dc.contributor.authorTURANLI, BESTE
dc.contributor.authorsTuranli, Beste; Grotli, Morten; Boren, Jan; Nielsen, Jens; Uhlen, Mathias; Arga, Kazim Y.; Mardinoglu, Adil
dc.date.accessioned2022-03-10T11:38:44Z
dc.date.available2022-03-10T11:38:44Z
dc.date.issued2018-05-15
dc.description.abstractDrug repositioning has gained attention from both academia and pharmaceutical companies as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have notorious adverse effects that drastically reduce the life quality of cancer patients so drug repositioning is a promising strategy to identify non-cancer drugs which have anti-cancer activity as well as tolerable adverse effects for human health. There are various strategies for discovery and validation of repurposed drugs. In this review, 25 repurposed drug candidates are presented as result of different strategies, 15 of which are already under clinical investigation for treatment of prostate cancer (PCa). To date, zoledronic acid is the only repurposed, clinically used, and approved non-cancer drug for PCa. Anti-cancer activities of existing drugs presented in this review cover diverse and also known mechanisms such as inhibition of mTOR and VEGFR2 signaling, inhibition of PI3K/Akt signaling, COX and selective COX-2 inhibition, NF-kappa B inhibition, Wnt/beta - Catenin pathway inhibition, DNMT1 inhibition, and GSK-3 beta inhibition. In addition to monotherapy option, combination therapy with current anti-cancer drugs may also increase drug efficacy and reduce adverse effects. Thus, drug repositioning may become a key approach for drug discovery in terms of time- and cost-efficiency comparing to conventional drug discovery and development process.
dc.identifier.doi10.3389/fphys.2018.00500
dc.identifier.issn1664-042X
dc.identifier.pubmed29867548
dc.identifier.urihttps://hdl.handle.net/11424/219784
dc.identifier.wosWOS:000432407100001
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SA
dc.relation.ispartofFRONTIERS IN PHYSIOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectprostate cancer
dc.subjectdrug repositioning
dc.subjectnon-cancer therapeutics
dc.subjectrepurposing
dc.subjectapproved drugs
dc.subjectVALPROIC ACID
dc.subjectZOLEDRONIC ACID
dc.subjectPHASE-II
dc.subjectANTICANCER AGENT
dc.subjectREPURPOSING ITRACONAZOLE
dc.subjectCARDIAC-GLYCOSIDES
dc.subjectANTITUMOR-ACTIVITY
dc.subjectALDOSE REDUCTASE
dc.subjectMETFORMIN USE
dc.subjectCELL LINES
dc.titleDrug Repositioning for Effective Prostate Cancer Treatment
dc.typereview
dspace.entity.typePublication
local.avesis.ided18eb1c-22b0-4b79-8093-b3cd88791427
local.import.packageSS4
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber500
local.journal.numberofpages20
local.journal.quartileQ2
oaire.citation.titleFRONTIERS IN PHYSIOLOGY
oaire.citation.volume9
relation.isAuthorOfPublication3e8c4f64-93ae-4b42-953c-35c8b07586b3
relation.isAuthorOfPublication.latestForDiscovery3e8c4f64-93ae-4b42-953c-35c8b07586b3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Turanli et al. - 2018 - Drug Repositioning for Effective Prostate Cancer T.pdf
Size:
1.99 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs